Skip to content
Cometriq(cabozantinib)
Cabometyx, Cometriq (cabozantinib) is a small molecule pharmaceutical. Cabozantinib was first approved as Cometriq on 2012-11-29. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2 and hepatocyte growth factor receptor. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Cabometyx, Cometriq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cabozantinib s-malate
Tradename
Company
Number
Date
Products
COMETRIQExelixisN-203756 RX2012-11-29
2 products, RLD
CABOMETYXExelixisN-208692 RX2016-04-25
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cabometyxNew Drug Application2021-01-31
cometriqNew Drug Application2020-10-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
renal cell carcinomaEFO_0000376D002292
Agency Specific
FDA
EMA
Expiration
Code
CABOZANTINIB S-MALATE, CABOMETYX, EXELIXIS INC
2028-09-17ODE-375
2026-01-14ODE-227
2024-09-17I-873
2024-01-22I-854
Patent Expiration
Patent
Expires
Flag
FDA Information
Cabozantinib S-Malate, Cabometyx, Exelixis Inc
97243422033-07-09DP
112983492032-02-10DP
100348732031-07-18U-2488
100397572031-07-18U-1480
88777762030-10-08DS, DPU-1617, U-3225
110914392030-01-15DP
110914402030-01-15DP
110980152030-01-15U-1220, U-1480, U-1617, U-2488, U-3225
75794732026-08-14DS, DP
84972842024-09-24U-1220, U-1480, U-2488
Cabozantinib S-Malate, Cometriq, Exelixis
97177202032-02-10DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
L01EX: Other protein kinase inhibitors in atc
L01EX07: Cabozantinib
HCPCS
No data
Clinical
Clinical Trials
223 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.051621122
Papillary thyroid cancerD000077273132118
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD00229213327553
Prostatic neoplasmsD011471C614123119
NeoplasmsD009369C80611118
Non-small-cell lung carcinomaD002289613117
Thyroid neoplasmsD013964EFO_0003841462112
Castration-resistant prostatic neoplasmsD06412946211
Neuroendocrine tumorsD018358EFO_1001901D3A.82719
AdenocarcinomaD0002301517
Urinary bladder neoplasmsD001749C67516
OsteosarcomaD0125161516
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatocellular carcinomaD006528C22.0469
Urologic neoplasmsD014571C64-C68458
Colorectal neoplasmsD015179547
Breast neoplasmsD001943EFO_0003869C50347
SarcomaD012509177
Kidney neoplasmsD007680EFO_0003865C64167
MelanomaD008545436
Ovarian neoplasmsD010051EFO_0003893C56335
Pancreatic neoplasmsD010190EFO_0003860C25235
Head and neck neoplasmsD006258234
Show 59 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.022
Hiv infectionsD015658EFO_0000764B2022
Healthy volunteers/patients22
Myelodysplastic syndromesD009190D4611
Hematologic neoplasmsD01933711
Non-hodgkin lymphomaD008228C85.911
Primary myelofibrosisD055728D47.411
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
B-cell chronic lymphocytic leukemiaD015451C91.111
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCABOZANTINIB
INNcabozantinib
Description
Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is a member of quinolines, an organofluorine compound, an aromatic ether and a dicarboxylic acid diamide.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Identifiers
PDB
CAS-ID849217-68-1
RxCUI1363268
ChEMBL IDCHEMBL2105717
ChEBI ID72317
PubChem CID25102847
DrugBankDB08875
UNII ID1C39JW444G (ChemIDplus, GSRS)
Target
Agency Approved
KDR
KDR
MET
MET
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
Clinical Variant
No data
Financial
Cabometyx - Exelixis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Cometriq - Exelixis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,323 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
375 adverse events reported
View more details